Business Update & Financial Outlook

Merck updated full-year 2023 guidance. Revenue Prior Guidance $57.7B to $58.9B -3% to -1% (-1% to +1% ex-FX) Updated Guidance $58.6B to $59.6B -1% to +1% (+1% to +3% ex-FX) Key Assumptions • Includes approximately $1B of LAGEVRIO revenue • Ex-LAGEVRIO, growth of 8% to 9% (10 to 11% ex-FX) Assumes 2 ppt FX headwind Non-GAAP Gross Margin Rate Non-GAAP ~77.0% ~77.0% • $23.3B to $24.1B $34.0B to $34.6B Operating Expenses¹ Other (Income) / Expense ~$250M of income ~$100M of expense Includes additional $10.2B related to upfront charge for the acquisition of Prometheus and investment to advance the acquired assets Includes financing costs related to the acquisition of Prometheus Tax Rate ~17.0% to 18.0% ~30.5% to 31.5% Includes ~15 ppt negative impact from the acquisition of Prometheus Shares Outstanding Non-GAAP EPS² ~2.55B $6.88 to $7.00 ~2.55B $2.95 to $3.05 • Assumes modest share repurchase Includes $4.02 one-time charge for the Prometheus acquisition and an additional $0.14 to advance the assets and finance the transaction Assumes 5 ppt FX headwind (additional $0.02 headwind) 1. Includes an aggregate $11.6 billion of R&D expenses related to the Prometheus and Imago acquisitions and upfront payment for the license and collaboration agreement with Kelun. Outlook does not assume any additional significant potential business development transactions. 2. Includes $4.53 of one-time charges related to the Prometheus and Imago acquisitions and upfront payment to Kelun. MERCK 17

View entire presentation